Damora Therapeutics Inc DMRA

US Biotechnology

$23.54 ▼ -2.20% ($-0.53)

Open $23.99

Prev Close $24.07

Day Range $23.52 – $24.77

52W Range $16.50 – $34.89

Market Cap $1.49B

Beta 1.16

EPS (TTM) $-139.34

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-29
Shares Out.	61,740,000
Website	damoratx.com ↗
Phone	17812819020
Employees	7
Revenue	$0
Gross Profit	$0
Net Income	-$32.0M
Free Cash Flow	-$59.1M
Total Assets	$532.6M
Total Liabilities	$36.9M
Equity	$495.8M

About Damora Therapeutics Inc

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Damora Therapeutics Inc is a publicly traded company under the ticker symbol DMRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.